01—Abstract
Summary
Summary of the 10-K filed March 14, 2006. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported net sales of $1,122.2 milliona for fiscal 2005, up 46.3% from $766.9 million in 2004, driven primarily by the October 2004 acquisition of Inveresk Research Group, with pro forma sales growth of 10.2%.
Operating income was $181.0 millionb (16.1% of net sales) versus $160.3 million (20.9%) in 2004, reflected $58.2 million of amortization of other intangibles, and net income rose to $142.0 million, or $1.96 diluted EPS, from $89.8 million ($1.68) a year earlier. Net income was helped by a $28.3 million net tax benefit tied to the American Jobs Creation Act repatriation and a change in assertion on Inveresk pre-acquisition earnings, and the effective tax rate fell to 10.3% from 40.1%. By segment, Research Models and Services contributed 44.8% of 2005 net sales, Preclinical Services 43.5% (up 83.6%), and Clinical Services 11.6%.
Management highlighted a 2006 capital expenditure plan of approximately $175 to $200 millionc for facility expansion, including a Massachusetts preclinical facility, a Nevada facility in 2007, and a California research models build-out. Backlog for Preclinical and Clinical Services was $448.2 million at December 31, 2005. Total debt fell to $296.7 million from $686.8 million after the conversion of $185 million of 3.5% convertible debentures into common stock and $337.5 million of debt repayments during 2005.
The company has not paid cash dividends in the past two years and does not intend to in the foreseeable future. Under a share repurchase program, the Board authorized a total of $100.0 milliond, of which about $82.5 million remained available at year-end. Risks highlighted in the filing include dependence on outsourcing trends and R&D budgets, customer contracts terminable on little notice, goodwill of $1.4 billion from the Inveresk acquisition, and foreign currency exposure, particularly to the pound sterling and Canadian dollar.
02—Key points
Key Highlights
- Net sales rose 46.3% to $1,122.2 million in 2005, primarily due to the Inveresk acquisition; pro forma sales growth was 10.2%.
- Operating income was $181.0 million (16.1% of net sales) versus $160.3 million (20.9%) in 2004, reduced by $58.2 million of intangible amortization.
- Net income was $142.0 million, or $1.96 diluted EPS, versus $89.8 million, or $1.68, in 2004, aided by a $28.3 million net tax benefit.
- Segment mix: Research Models and Services 44.8%, Preclinical Services 43.5%, Clinical Services 11.6% of 2005 net sales.
- Planned 2006 capital expenditures of approximately $175 to $200 million to expand facilities, including new Massachusetts and Nevada preclinical sites.
- Total debt reduced to $296.7 million from $686.8 million; $185 million of 3.5% convertible debentures converted into common stock.
- Backlog for Preclinical and Clinical Services was $448.2 million at December 31, 2005; no dividends paid and none planned.
03—Questions
Frequently Asked Questions
How much did Charles River's revenue grow in 2005 and what drove it?
Net sales were $1,122.2 million in 2005, up $355.3 million, or 46.3%, from $766.9 million in 2004. The filing attributes the increase primarily to the Inveresk acquisition completed in October 2004, along with organic growth in all segments. Pro forma sales growth was 10.2%.
Why did operating margin decline even though sales grew?
Operating margin fell to 16.1% from 20.9%. The filing cites amortization of intangibles related to Inveresk of $53.9 million, stock-based compensation tied to Inveresk of $7.8 million, and a mix shift toward Preclinical and Clinical services, which traditionally carry lower margins than the Research Models and Services segment.
Why was the 2005 effective tax rate so low?
Income tax expense was $16.6 million, or 10.3% of pre-tax income, compared with 40.1% in 2004. The filing attributes the decrease mainly to a net benefit of $28.3 million from the AJCA distribution of $24.1 million and the change in assertion on Inveresk pre-acquisition earnings of $29.2 million, offset by a $23.1 million charge from restructuring UK operations.
Does the company pay dividends or repurchase shares?
The company has not declared or paid cash dividends in the past two years and does not intend to pay them in the foreseeable future. Its Board authorized share repurchases of up to $100.0 million total, and about $82.5 million remained available at the end of 2005 after repurchases of 340,000 shares for about $14.9 million in the fourth quarter.
What are the main risks to the business according to the filing?
Key risks include a slowdown in outsourcing of preclinical and clinical work, reductions in pharmaceutical R&D or government research funding, customer contracts that can be terminated on little or no notice, possible goodwill impairment on the $1.3 billion of goodwill added through Inveresk, and currency fluctuations, particularly the pound sterling and Canadian dollar.
04—Continue